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Abstract
Use of the antitumor drug doxorubicin is limited by cardiomyopathic side-effects
which are believed to be due to iron-mediated hydroxyl radical generation. Dexrazoxane
reduces this cardiotoxicity, possibly by removal of iron from doxorubicin by the EDTA-like
hydrolysis product of dexrazoxane, ADR-925. However, EDTA-diimides like dexrazoxane,
previously used as antitumor agents, are themselves carcinogenic, and recent studies have
found that Fe-ADR-925 can also promote hydroxyl radical production. This study
demonstrates that, like Fe-EDTA, Fe-ADR-925 and a related desmethyl complex can cleave
plasmid DNA under Fenton conditions, and suggests by radical scavenger study that this
cleavage is probably via the hydroxyl radical. Differences in DNA cleavage dependence
upon concentrations of Fe-EDTA, Fe-ADR-925 and Fe-EDTA-bisamide can be explained by
differences in the solution chemistry of the complexes.
Introduction
Dexrazoxane (Zinecard, Cardioxane, ADR-529, ICRF-187), 1, reduces the
cardiomyopathic effects of the antitumor antibiotic doxorubicin (Adriamycin), effective!y
raising the lifetime maximum dose of doxorubicin. The cardiotoxicity of doxorubicin =s
believed to be due to an iron-mediated production of reactive hydroxyl radicals, HO..3which have been associated with lipid peroxidation and protein and nucleic acid cleavage. It is
generally thought that the nonpolar dexrazoxane hydrolyzes intracellularly to 2 (ADR-925), a
polar bisamide/bisacid analog of the metal ion chelator EDTA (3), reducing the availability
of iron to doxorubicin and, hence, the production of hydroxyl radicals." In addition to the
enantiomerically-pure dexrazoxane both its racemate razoxane (ICRF-159) and its desmethyl
form (ICRF-154, EDTA-diimide, ,), are alone effective against murine tumor models.
4,5
Razoxane was previously used to treat breast masses as well as psoriasis, but treatment with
EDTA-diimide derivatives led to generalized carcinogenesis as therapy-related leukemia. 5’6
Like doxorubicin, razoxane is thought to target topoisomerase II (although by a different
mechanism); however it was shown to hydrolyze intracellularly and was initially thought to be
involved in metal ion chelation. 7-1
Dexrazoxane is prescribed at lower doses in cardioprotection (500-600 mg/m2) than
razoxane was as an antineoplastic (500-1500 mg/m2), but an important therapeutic issue is
the limit of the ability of dexrazoxane to reduce doxorubicin-related toxicity, especially since
razoxane was shown to act synergistically with doxorubicin as an antitumor agent.’ Indeed,
Imondi et al. recently showed that proportionally greater doses of dexrazoxane are poorer
inhibitors of cardiomyopathy at increasing doses of doxorubicin in animal models.
3 Hasinoff
and Winterbourn have illustrated the ability of the hydrolysis product of razoxane (ICRF-198,
the racemate of ADR-925) to remove iron(Ill) from doxorubicin, and there is recent evidence
that the iron-bound hydrolysis product of dexrazoxane is involved in hydroxyl-radical
production.
4, Winterbourn, et al., illustrated this production by showing oxidation of small,
organic molecules in the presence of Fe-ADR-925 comparable to Fe-EDTA.1 Hasinoff and
associates have shown that this can involve direct reaction of doxorubicin to reduce the Fe-
ADR-925 and have additionally suggested that Fe-ADR-925 produces hydroxyl radicals more
slowly than Fe-EDTA.6,7
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Fe-ADR-925 is presumed to react like Fe-EDTA under Fenton conditions (in the
presence of oxidant and reductant).
15 The Fenton reaction involves reduction of the ferric
species to the corresponding ferrous species, followed by reduction of dioxygen to hydrogen
peroxide or reduction of hydrogen peroxide to a hydroxide and hydroxyl radical; other
electron-deficient species may also be produced, depending, upon the ron ligand.
3 In
particular, these reactive, oxidizing species are exploited n nucleic acid and protein
cleavage studies, and it has specifically been illustrated that Fe-EDTA cleaves DNA under
Fenton conditions via the hydroxyl radical. 3,18
Since doxorubicin is a DNA intercalator, it is reasonable to think that some of the
hydroxyl radicals produced by the doxorubicin oxidize and cleave DNA in vivo, and this may
account in part for the cardiotoxicity of doxorubicin. However, since Fe-ADR-925 produces
hydroxyl radicals similarly to Fe-EDTA, it is of great importance to consider whether this iron-
bound hydrolysis product of dexrazoxane can also cleave DNA. A particularly useful assay
for hydroxyl radical damage to DNA is the nicking of a supercoiled plasmid.
19-23 The
supercoiled form (form I) of the plasmid can readily be separated from plasmid that has been
cleaved in a single-stranded manner (nicked, form II)and in a double-stranded manner
(linear, form III) by agarose gel electrophoresis. This study investigates the ability of iron-
bound ADR-925 and its desmethyl derivative EDTA-bisamide (5) to cleave supercoiled
plasmid DNA in the presence of the reductant ascorbic acid under aerobic conditions.
Additionally, thiourea, known to be a radical scavenger, is used to probe the mechanism of
DNA cleavage.
Materials and Methods
Materia/s. EDTA-dianhydride, thiourea, Na2Fe"EDTAT2HO, aqueous glycerol and boric acid
(Aldrich); ascorbic acid and FeCI (Baker); Tris and bromphenol blue (BioRad); conc. NH4OH,
NaCI and NaEDTA (Fisher); agarose (EEO 0.9-0.13) and ethidium bromide (Sigma) were
obtained in their highest available purity and used without further purification. ADR-925 (2)
was generously provided by Pharmacia/Upjohn. Universal buffer was from Stratagene, and
EcoR and pBR322 plasmid solution (0.25g/L, 10 mM Tris HCI, 5 mM NaCI, 0.1 mM
EDTA, pH 7.4) were from GibcoBRL. Bamsted Nanopure (18 MD. cm) water was used
throughout, and all reaction equipment was acid-washed in 4.5 M HCI or concentrated
sulfuric acid, or purchased metal-free.
Instrumentation. NMR spectra were obtained using a Varian Gemini 2000 200 MHz
Spectrometer equipped with a Sun Workstation. UV-VIS sp.ectra were acquired on an Oils
Cary-14 spectrophotometer interfaced to a Dell 310 mtcrocomputer. IR spectra were
obtained using a Perkin Elmer 1600 Series FTIR spectrophotometer. Solution sample and
reaction pH were monitored with a Corning Model 340 pH meter equipped with a Corning
combination electrode. Electrophoresis. was carried out in a Submarine Mini-gel
Electrophoresis Unit (Sigma) with a BioRad PowerPac 300. Gels were visualized with an IS-
1000 Digital Imaging System (Alpha Innotech Corp.).
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Preparation of EDTA-bisamide (5). Ethylenediaminetetraacetic acid dianhydride (6.60 g,
25.8 mmol) was slowly stirred into an ice-cold 20 mL portion of concentrated (28-30%)
ammonium hydroxide. At room temperature, an additional mL of conc. ammonium
hydroxide was added, followed by 20 mL of water and 12-24 h of stirring. Solvent was then
removed under reduced pressure, and the white solid was redissolved in 20 mL water and
precipitated with concentrated HCI. This was filtered under vacuum, washed twice with dry
diethyl ether and .vacuum desiccated overn!ght. Analysis: yields >75%; IR carbonyl bands
(KBr): 1645.8 cm-
(CONH)and 1680.4 cm-
(COOH); H NMR (DO; DSS internal standard)
resonances: 2.9 ppm--(-CH), 3.35 ppm (CH._CO’),o 3.5 ppm (C_.HCONH).
Preparation and Characterization of Iron Complexes. Fe-EDTA was used as purchased. Fe-
EDTA-bisamide and Fe-ADR-925 were freshly-prepared 10x in situ by mixture of appropriate
amounts of EDTA-bisamide or ADR-925 (0.2 M stock) and ferrous chloride (0.04 M stock) and
maintained at pH 5. Resulting solutions were diluted into water for immediate use. EDTA-
bisamide and ADR-925 were used at 500 pM regardless of iron concentration, which was at
least in 4-fold excess over the iron complex. In aqueous solution, these complexes exist in
both monomeric and dimeric forms. At pH 5, the iron(Ill) EDTA-bisamide and ADR-925
monomers show one absorbance maximum at 258 nm. The dimeric complexes (pH 7)
exhibit shoulders at 247 nm, 271 nm, 308 nm, and 341 nm and a maximum in the visible
region at 475 nm and 540 nm (sh).
Base titrations were carried out at 23 C and over pH ranges 4.0-6.9 and 4.2-8.2 for
Fe-EDTA-bisamide and Fe-ADR-925, respectively. At higher pH, the iron complexes become
unstable towards precipitation. Iron(Ill) complexes (100 pM) were generated in situ by the
addition of 1:1 ferrous chloride to a stock solution of the ligand (pH~5) and aerially oxidized
to the iron(Ill) form over approximately 24 hrs. Throughout the titration, standardized,
carbonate-free NaOH(aq) (0.1 M)was added with continuous stirring and under a blanket of
N to raise the pH approximately 0.2 units. Spectra and pH readings were obtained 10
minutes after each addition of base. During this 10 min. interval, the pH drops and
minimizes; kinetics of similar pH-jump experiments indicate dimer formation maximizes in 10
min., after which time a slower secondary process (most likely re-equilibration with the
monomer species)takes place. Titrations at higher metal-complex concentrations, needed
for monitoring dimer formation at 475 nm, were unsuccessful due to precipitation.
Nicking Reactions. Each 20 pL reaction was 10.2 mM Tris HCI, 50.4 mM NaCI, 2.5 pM
EDTA, 0.1 mM ascorbate, 10 pM in base pairs of DNA, specified concentration of iron
reagent and excess ligand, pH 7. The DNA used was the pBR322 plasmid from E. coli, which
is 4,361 base pairs and has a single, unique recognition site for the EcoR endonuclease
(which cleaves DNA in a double-stranded manner). Tris/NaCI buffer (pH 7)with thiourea
when appropriate (17.5 pL) and DNA solution (0.5 pL) were combined in a picofuge tube; 1.0
L of freshly-prepared ascorbate (2 mM, pH 7) and 1.0 pL of freshly-prepared iron-reagent
solution were placed on the side of the tube, and all reactions for each experiment were
started nearly simultaneously by shaking the components of each tube together. Reactions
proceeded at room temperature for 60 min, and each was stopped by the addition of 5 pL of
a solution of 0.25% bromphenol blue in 30% aqueous glycerol and electrophoresed
immediately.
(A) To confirm the relative electrophoretic mobilities of plasmid forms I, II and III,
reactions with no iron reagent, with 100 pM ferrous chloride and with a standard 20 pL EcoR
digest were performed. (B) Fe-EDTA was studied at pM, 10 ILtM, and 100 l.tM in the
absence of thiourea. (C) Fe-EDTA-bisamide was studied at pM, 10pM, 50 pM and 100 pM
in the absence of thiourea. (D) Fe-ADR-925 was studied at 10 pM, 50 l.tM and 100 pM in the
absence of thiourea. (E) In the presence of 5 mM and 500 mM thiourea, Fe-EDTA and Fe-
EDTA-bisamide were studied at 10 pM.
For cleavage product analysis, gels were 1% agarose in 0.5x TBE (45 mM Tris-
borate, mM EDTA, pH 7.75), and electrophoresis was conducted at room temperature in
0.5x TBE at 50 V for 3.5 h. After electrophoresis, gels were stained in 0.5 ILtg/mL ethidium
bromide for h and then imaged and analyzed densitometrically under ultraviolet light. Note
that small differences in staining make exact quantitative gel-to-gel comparisons difficult.
Densitometry is uncorrected for differential uptake of ethidium bromide by supercoiled and
non-supercoiled DNA. A previous study with pBR322 plasmid under similar conditions
showed this factor was small. -4
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Results of DNA Cleavage Experiments
Controls indicated that plasmid not treated with iron reagent or endonuclease was at
least 80% supercoiled. Treatment with 100 #M ferrous chloride in the absence of ligand
resulted in two bands of approximately equal densitometric intensity (the faster-migrating
corresponding to the 80+% band on the control), and endonuclease digestion resulted in a
single intermediate band. This indicates that under the electrophoretic conditions chosen,
supercoiled DNA migrates the fastest, linear DNA migrates intermediately, and nicked DNA
migrates most slowly.
Table I. Cleavage of pBR322 Plasmid With
Varying Concentrations of Fe-EDTA and
Fe-EDTA-bisamide.
iron conc. form (%)
reagent (laM) II III
’Fe2/ 100 35 64
Fe-EDTA 100 0 94 6
Fe-EDTA 10 3 88 9
Fe-EDTA 25 69 6
Fe-EDTAba 100 10 84 6
Fe-EDTAba 10 3 87 10
Fe-EDTAba 41 59 0
Relative densitometric intensities from UV
imaging after ethidium bromide staining. DNA
(10 # M bp),buffer (10 mM Tris HCI, 50 mM NaCI,
Table I1. Cleavage of pBR322
Plasmid With Fe-EDTAMsamide anc
Fe-ADR-925.
iron conc. form (%)
reagent (#M) II III
Fe2/ 100 30 70 0
Fe-EDTAba 100 14 81 5
Fe-EDTAba 50 7 88 5
Fe-EDTAba 10 7 86 7
Fe-ADR-925 100 4 91 5
Fe-ADR-925 50 6 89 5
Fe-ADR-925 10 13 82 5
Relative densitometric intensities fr
2.5 ta M EDTA, pH 7), ascorbate (100 mM) and UV imaging after ethidium bromide
iron reagent reacted at room temperature for 60 min. staining. Same conditions as in Ta
Form II
Form II
Figure 1. UV-visualized agarose gel of the pBR322 plasmid cleavage products after reaction with Fe-
EDTA and Fe-EDTA-bisamide (1-100 M). Supercoiled DNA is Form I, nicked is Form II, and linear is
Form II1.
DNA was cleaved by the Fe-EDTA-bisamide under Fenton conditions. At 100 pM, Fe-
EDTA and Fe-EDTA-bisamide both cleaved the plasmid with greater efficiency than ferrous
chloride (Table I). At 10 #M, Fe-EDTA and Fe-EDTA-bisamide cleaved the DNA with
approximately equal efficiency. However, Fe-EDTA cleaved the DNA more efficiently than
Fe-EDTA-bisamide at both #M and 100 #M; this is especially unusual, since Fe-EDTA-
bisamide cleaved the DNA less efficiently at 100 l.tM (the higher concentration) than at 10
l.tM (Figure 1). Fe-ADR-925 (the iron-bound hydrolysis product of dexrazoxane) was also able
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to cleave DNA (Table II), and did so with approximately equal efficiency to Fe-EDTA-
bisamide at 50 #M. However, like Fe-EDTA, Fe-ADR-925 cleaves DNA with increasing
efficiency as concentration increases between 10 l.tM and 100 l.tM (as opposed to Fe-EDTA-
bisamide).
Table III. Thiourea Inhibition of Cleavage of pBR322
Plasmid by Fc+, Fe-EDTA and Fe-EDTAbisamide.
iron thiourea form (%)
reagent conc. (mM) II III
Fe2+ 0 49 51 0
Fe2+ 5 81 19 0
Fe-EDTA 0 0 97 3
Fe-EDTA 5 53 47 0
Fe-EDTA 500 92 8 0
Fe-EDTAba 0 0 95 5
Fe-EDTAba 5 48 52 0
Fe-EDTAba 500 88 12 0
Relative densitometric intensities from UV imaging after
ethidium bromide staining. Iron reagent is 10 # M. Other
conditions same as Table 1.
Figure 2 Thiourea inhibition of DNA cleavage by Fe2/, Fe-EDTA and Fe-EDTA-bisamide. Iron reagents
were 10 #M, and thiourea was 0-500 mM (thiourea concentration is indicated over each lane). Same
visualization as in Figure 1.
The cleavage of DNA in the presence of ferrous chloride, Fe-EDTA and Fe-EDTA-bisamide
(all at 10 #M) was inhibited by the radical scavenger thiourea (Table III). At 5 mM thiourea,
cleavage by ferrous chloride was almost entirely retarded, and cleavage by Fe-EDTA and Fe-
EDTA-bisamide was reduced by half. Thiourea at 500 mM approximately completely
prevented DNA cleavage (Figure 2).
Discussion
Razoxane, like other EDTA-diimide drugs (ICRF-154, dexrazoxane), is an
antineoplastic, and this is probably due at least in part to inhibition of topoisomerase II. 5,7 At
lower doses, dexrazoxane, which is simply enantiomerically-pure razoxane, ameliorates the
cardiotoxicity of doxorubicin therapy. However, such diimides are also carcinogenic, and
both razoxane and dexrazoxane hydrolyze in vivo to metal-ion chelators that can produce
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hydroxyl radicals when bound to iron under Fenton conditions. 6,1,15 This study illustrates that
this chemistry can cleave DNA, and further suggests that this DNA cleavage is by hydroxyl
radical, since it is inhibited by the radical scavenger thiourea.
a) b)
Figure 3 Ultraviolet absorption spectral changes for a) Fe-EDTA-bisamide and b) Fe-ADR-925 upon base
titration. Iron complexes were 100 IM. The pH ranges were 4.0-6.9 for Fe-EDTA-bisamide and 4.2-8.2 for
Fe-ADR-925. At higher pHs, the iron complexes become unstable toward iron hydroxide and oxide
formation and precipitation.
Our lab has observed that high (preparative) concentrations of ferrous chloride and
EDTA-bisamide result in an initially yellow solution that turns brown over time at relatively
low pH. UV studies have indicated that this is a secondary base-catalyzed reaction after
complex formation, and spectrophotometric similarities between this reaction and formation
of the Fe-EDTA p-.oxo dimer suggest that such iLt-OXO dimerization may be occurring with Fe-
EDTA...bisamide and Fe-ADR-925, as well (Figure 3). Dimer formation for Fe-ADR-925 begins
at higher basicity (pH~6)than for Fe-EDTA-bisamide (pH~5), perhaps because the methyl
substituent on ADR-925 decreases the Lewis acidity of the iron in that complex.
5 Attempts to
determine dimerization constants by spectrophotometric titrations have been hindered by
precipitation problems under the conditions needed for this analysis.e Further attempts to
obtain these constants kinetically have likewise proven difficult due to mechanistic
complexities. More work is needed, and a full analysis of this system is ongoing in our lab.
The higher pHs at which Fe-EDTA and Fe-ADR-925 undergo monomer-dimer equilibrium,
however, correspond well with the differential concentration/cleavage profiles of Fe-EDTA-
bisamide, Fe-ADR-925 and Fe-EDTA. The inhibition of these DNA scission reactions by
thiourea probably does not rule out either additional oxidizing species or modes of inhibition
in addition to radical scavenging. In particular, thiourea might react with other electron-
deficient species that could cleave DNA, and might also be binding to the metal center.
The former is particularly worth further investigation since the ferryl species [FeV=O(EDTA
bisamide)] would be neutral as opposed to [Fe=O(EDTA)]-, which would be negative (same
as the DNA backbone).
We would like to suggest that the ability of the iron-bound hydrolysis products of
dexrazoxane and ICRF-154 to cleave DNA might account for the carcinogenic nature of the
diimide drugs, and this implies a therapeutic limit to dexrazoxane. Furthermore, it does not
seem clear at this time that such a route might not also be a substantial contributor to the in
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vivo mechanism of the antitumor activity by razoxane. Most importantly, the production of
the very same oxidizing species, HO, thatis taken to be responsible for doxorubicin toxicity
at least suggests that there may be a maximum dose for doxorubicin/dexrazoxane
combination. Moreover, the relative ease with which Fe-EDTA-bisamide and Fe-ADR-925
form dimers at near physiological pH suggests that the local concentration in vivo may be
important to the iron-bound drug’s overall reactivity. This calls for further chemical and,
especially, clinical study.
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